Home » Stocks » ACAD

ACADIA Pharmaceuticals Inc. (ACAD)

Stock Price: $21.63 USD -0.66 (-2.96%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $21.80 +0.17 (0.79%) Jul 30, 5:54 PM
Market Cap 3.46B
Revenue (ttm) 458.24M
Net Income (ttm) -260.01M
Shares Out 160.01M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $21.63
Previous Close $22.29
Change ($) -0.66
Change (%) -2.96%
Day's Open 22.13
Day's Range 21.63 - 22.58
Day's Volume 1,088,761
52-Week Range 19.20 - 57.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double...

1 week ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S....

1 week ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer's Associati...

2 weeks ago - Business Wire

New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acad...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - June 19, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: Jun...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acad...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 17, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceutica...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 17, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceutical...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) a...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Co...

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 15, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) an...

1 month ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2...

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 0 1 Somewhat Bullish 0 0 1 1...

1 month ago - Benzinga

Los Angeles, California--(Newsfile Corp. - June 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 8, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceutical...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) al...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 4, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ...

1 month ago - Newsfile Corp

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

San Francisco, California--(Newsfile Corp. - June 3, 2021) -  Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: Ju...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

1 month ago - Newsfile Corp

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated w...

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

1 month ago - Newsfile Corp

We believe that the stock price of ACADIA Pharmaceuticals, a biopharmaceutical company focused on neuroscience drugs, looks undervalued at current levels of around $22. ACAD stock is actually down 37% f...

1 month ago - Forbes

Acadia Healthcare (ACHC) is gaining from rise in revenues, several acquisitions and joint ventures as well as robust cash flows.

Other stocks mentioned: ACHC
2 months ago - Zacks Investment Research

Los Angeles, California--(Newsfile Corp. - June 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

2 months ago - Newsfile Corp

NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of it...

2 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - May 31, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on the behalf of investors who purchased Acadia Pharmaceuticals I...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - May 31, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 31, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) al...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - May 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadi...

2 months ago - Newsfile Corp

NEW YORK, May 28, 2021 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmac...

2 months ago - PRNewsWire

LOS ANGELES, May 28, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Aca...

2 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals ...

2 months ago - Newsfile Corp

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: Jefferies 2021 Virtual Healthcare Conference Firesi...

2 months ago - Business Wire

San Francisco, California--(Newsfile Corp. - May 24, 2021) -  Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: Ju...

2 months ago - Newsfile Corp

BENSALEM, Pa., May 24, 2021 /PRNewswire/ -- Law Offices of Howard G.

2 months ago - PRNewsWire

San Francisco, California--(Newsfile Corp. - May 20, 2021) -  Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: Ju...

2 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - May 17, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June...

2 months ago - Newsfile Corp

LOS ANGELES, May 13, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  June 18, 2021  deadline to file a lead plaintiff motion in the case filed on behalf of i...

2 months ago - PRNewsWire

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive a... [Read more...]

Industry
Biotechnology
IPO Date
May 27, 2004
CEO
Stephen Davis
Employees
640
Stock Exchange
NASDAQ
Ticker Symbol
ACAD
Full Company Profile

Financial Performance

In 2020, ACAD's revenue was $441.76 million, an increase of 30.28% compared to the previous year's $339.08 million. Losses were -$281.58 million, 19.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 27.21, which is an increase of 25.80% from the latest price.

Price Target
$27.21
(25.80% upside)
Analyst Consensus: Buy